摘要
目的观察重组人血管内皮抑制素注射液(恩度)联合化疗治疗宫颈癌的临床疗效。方法将19例宫颈癌患者给予紫杉醇、顺铂联合恩度治疗,2周期治疗后进行影像学检查评价疗效。结果患者有效率(RR)为57.9%,疾病控制率(DCR)为84.2%,主要不良反应为骨髓抑制。结论恩度联合化疗治疗宫颈癌,可提高总有效率,不良反应少,有望成为宫颈癌治疗的新手段。
Objective To observe the clinical efficacy of Endostar combined with chemotherapy in treatment of cervical cancer. Methods 19 cases of cervical cancer patients given paclitaxel combined with cisplatin and Endostar for the treatment. After 2 cycles of treatment,imaging examination was performed to evaluate the efficacy. Results The patient＇s effective rate（RR）was 57.9%,disease control rate（DCR）was 84.2%,and the main side effects were bone marrow suppression. Conclusion Endostar combined with chemotherapy in the treatment of cervical cancer,can improve the total efficiency,does not increase the adverse reactions,is expected to become new means of treatment of cervical cancer.
出处
《中国卫生标准管理》
2016年第20期114-115,共2页
China Health Standard Management
关键词
重组人血管内皮抑制素注射液
宫颈癌
化疗
Human recombinant endostatin injection
Cervical cancer
Chemotherapy
